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Abstract
Background
Data on initiation and utilization of direct-acting antiviral therapies for hepatitis C virus
infection in the United States are limited. This study evaluated treatment initiation, time to
treatment, and real-world effectiveness of direct-acting antiviral therapy in individuals with
hepatitis C virus infection treated during the first 2 years of availability of all-oral direct-acting
antiviral therapies.
Methods
A retrospective cohort analysis was undertaken using electronic medical records and chart
review abstraction of hepatitis C virus-infected individuals aged >18 years diagnosed with
chronic hepatitis C virus infection between January 1, 2014, and December 31, 2015 from
the Indiana University Health database.
Results
Eight hundred thirty people initiated direct-acting antiviral therapy during the 2-year observa-
tion window. The estimated incidence of treatment initiation was 8.8%±0.34% at the end of
year 1 and 15.0%±0.5% at the end of year 2. Median time to initiating therapy was 300 days.
Using a Cox regression analysis, positive predictors of treatment initiation included age
(hazard ratio, 1.008), prior hepatitis C virus treatment (1.74), cirrhosis (2.64), and history
of liver transplant (1.5). History of drug abuse (0.43), high baseline alanine aminotransfer-
ase levels (0.79), hepatitis B virus infection (0.41), and self-pay (0.39) were negatively
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associated with treatment initiation. In the evaluable population (n = 423), 83.9% (95% confi-
dence interval, 80.1–87.3%) of people achieved sustained virologic response.
Conclusion
In the early years of the direct-acting antiviral era, <10% of people diagnosed with chronic
hepatitis C virus infection received direct-acting antiviral treatment; median time to treatment
initiation was 300 days. Future analyses should evaluate time to treatment initiation among
those with less advanced fibrosis.
Introduction
Hepatitis C virus (HCV) infection is the most common blood-borne infection in United States,
with approximately 2.2 to 3.8 million persons infected nationwide [1]. Left untreated, HCV
infection can cause cirrhosis or hepatocellular carcinoma, and may lead to liver transplant or
death [2]. Before 2011, interferon-based therapies were the main treatment for HCV infection,
yielding sustained virologic response (SVR, or cure) rates of approximately 45% to 50% [3].
The introduction of first-generation direct-antiviral agents (DAA), administered with pegy-
lated interferon and ribavirin, improved SVR rates to approximately 50% to 75% in treatment-
naive individuals with genotype (GT) 1 infection [4–6]. However, the improvements in SVR
attained with first-generation agents were associated with an increased frequency of adverse
events. In 2013, simeprevir and sofosbuvir were approved for the treatment of HCV infection
[7]. Although not approved as a combination regimen, the off-label use of these agents led to
the first all-oral DAA therapy for HCV GT1 infection. In addition, sofosbuvir plus ribavirin
was approved for the treatment of GT2 and GT3 infection [8]. Subsequently, ledipasvir/sofos-
buvir and ombitasvir, paritaprevir, and dasabuvir were approved in the United States and
Europe. These agents offered short-duration, interferon-free treatments that could be adminis-
tered with or without ribavirin and achieved SVR rates of>90% [9–14].
Additional barriers to the real-world treatment of HCV infection exist that are often con-
trolled for in clinical trials. Real-world treatment of HCV infection may be complicated by
comorbidities and concomitant medications, and economic considerations can prevent the
successful initiation or completion of DAA-based therapy [15–18]. To date, data are limited
concerning the proportion of HCV-infected individuals who are eligible for DAA treatment or
who have initiated treatment, and few reports have evaluated the time to treatment initiation
following diagnosis. The objectives of this study were to evaluate treatment initiation rates,
time to treatment, and predictors of initiating treatment in individuals receiving all-oral DAA
therapy in a real-world setting. Real-world effectiveness of all-oral DAA regimens and early
discontinuation rates were also assessed.
Methods
This was a retrospective cohort analysis using electronic medical records (EMRs) and chart
review abstraction of HCV-infected individuals from the Indiana University health database,
which included data from 48,000 persons in 2015. The study was conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice guidelines, and the protocol was
approved by the Indiana University Office of Research Compliance institutional review board.
Data regarding prior HCV treatment and comorbidities were captured through the Indiana
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Network for Patient Care, a health information exchange containing data from multiple Indi-
ana healthcare institutions. Manual chart reviews were performed to validate HCV genotype,
treatment start and end dates, and clinical characteristics including HCV RNA viral load,
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels, and platelet
counts. A waiver of the informed consent process was approved by the appropriate institu-
tional review board.
Study population
Individuals aged>18 years with a documented ICD-9 and/or ICD-10 code (International
Classification of Diseases, 9th or 10th edition, Clinical Modification) of non-acute HCV infec-
tion and a documented encounter between January 1, 2014, and December 31, 2015 (the
cohort identification period) were included. All participants with at least one record of an
all-oral DAA prescription filled during the cohort identification period were included in the
DAA-treated cohort. End-of-treatment for participants enrolled during the cohort identifica-
tion period could extend to March 31, 2016. DAA regimens in this study included sofosbuvir/
ledipasvir ± ribavirin, paritaprevir/ritonavir/ombitasvir/dasabuvir (PrOD) ± ribavirin, sofos-
buvir/simeprevir ± ribavirin, and sofosbuvir + ribavirin. Participants were required to have
�6 months of historical records prior to the treatment index date, which was defined as the
time at which an individual first received all-oral DAA treatment during the study period.
Individuals receiving concurrent interferon therapy were excluded from the DAA-treated
cohort.
HCV-infected individuals with no record of all-oral DAA treatment were included in the
HCV untreated cohort.
Study measures
Baseline characteristics, prior HCV treatment, and HCV genotype were recorded. HCV geno-
type, fibrosis level, AST:platelet ratio index (APRI), intended treatment duration, and treat-
ment completion duration were extracted from medical chart reviews. Fibrosis level was based
on the APRI and Fibrosis 4 (FIB-4) indices. The FIB-4 score was calculated based on variables
recorded before the DAA index date, using the following formula:
FIB-4 ¼ age ½years� � AST ½IU=L�=platelet count ½�109=L� � ðALT1=2½IU=L�Þ
APRI score was calculated via the following formula:
APRI ¼ aminotransferase=normality upper limit=platelet ½109=L� � 100
Cirrhosis was defined as a FIB-4 score of>3.5. Co-morbidities such as hepatitis B virus
infection, HIV, and history of kidney or liver transplant were defined by the presence of at
least one ICD-9 CM or ICD-10 CM code during the baseline period of 1 year prior to and
including the index date.
Study outcomes
Treatment initiation rates and time to treatment were calculated using the time from the first
clinical encounter of HCV diagnosis to the first medication order of a DAA agent. Early treat-
ment discontinuation was defined as an observed treatment duration minus treatment gap
that was shorter than intended treatment duration by 14 days. SVR12 was defined as undetect-
able HCV RNA 12 weeks after the end of treatment, and end of treatment was calculated as the
last date covered by prescription using medication dispensed information and number of days
Real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection
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for which medication was supplied. SVR12 was calculated for the evaluable population (all par-
ticipants with an available treatment outcome who completed the planned regimen or discon-
tinued early) and the per-protocol population (all participants with an available treatment
outcome who completed treatment).
Statistical analysis
Descriptive statistics and univariate analysis were used to describe the distribution of demo-
graphics and clinical and laboratory characteristics. Time to treatment was used to estimate
the cumulative percentage of eligible HCV-infected individuals receiving DAA prescriptions.
Individuals with no DAA prescription were assumed to have not received any treatment at
Indiana University until the last encounter in the EMR, at which point the observed time to
treatment was censored. Kaplan–Meier analysis was used to estimate the percentage of partici-
pants receiving prescriptions at any time from the first clinical encounter.
Univariate analysis was used to identify factors significantly associated with DAA prescrip-
tion using t tests and chi-square tests. Cox regression analysis was used to predict factors asso-
ciated with time to initiation of therapy. SAS (version 9.4, SAS Institute Inc., Cary, NC, USA)
and Stata version 11 (Stata Corp., College Station, TX, USA) were utilized to conduct analyses.
Results
A total of 8,611 individuals with a diagnosis of chronic HCV, or a pharmacy order for a DAA
agent between January 1, 2014, and December 31, 2015, were identified. After applying inclu-
sion/exclusion criteria, 8,407 individuals with chronic HCV infection were included, of whom
830 initiated DAA therapy and 7,577 did not, resulting in a treatment initiation rate of 9.9%.
Individuals in the DAA-treated cohort were older than those in the untreated cohort
(median age, 57 years versus 52 years, p<0.0001), and there were fewer women in the treated
versus untreated cohort (39.5% versus 45.3%, p = 0.0014) (Table 1). Most were white (DAA-
treated cohort, 79.9%; untreated cohort, 79.2%) and had HCV GT1a infection (56.1% vs.
60.8%). Compared with the untreated cohort, people in the treated cohort were more likely to
have cirrhosis (43.5% vs. 15.4%, p<0.0001), a higher severity of Charlson comorbidity index
(p<0.0001), and a history of kidney (1.7% vs. 0.7%, p = 0.0024) or liver transplant (14.1% vs.
4.4%, p<0.0001). Fewer people in the DAA-treated cohort had a history of depression (7.6%
vs. 11.7%, p<0.0003) or drug abuse (5.8% vs. 12.7%, p<0.0001) compared with the untreated
cohort. A higher percentage of individuals in the DAA-treated cohort had previously received
interferon-based therapies compared with the untreated cohort (25.5% vs. 7.1%, p<0.0001).
Proton pump inhibitor use was lower in the treated compared with the untreated cohort
(36.9% vs. 42.4%, p = 0.0022).
Time to treatment initiation and factors associated with treatment
initiation
At year 1, the estimated incidence of treatment initiation was 8.80% ± 0.34%, and at year 2,
this increased to 15% ± 0.5%. The median time to DAA initiation was 300 days among those
who received treatment within the 2-year observation window (Fig 1), ranging from 25 to 675
days with a distribution as shown in S1 Fig. Sofosbuvir/ledipasvir ± ribavirin was the most
commonly initiated treatment, comprising 382/830 (46%) of all treatments started, followed
by sofosbuvir/ribavirin (25.7%) and sofosbuvir/simeprevir ± ribavirin (22.5%) (Table 2).
Positive predictors of treatment initiation included age (hazard ratio [HR] 1.01), treatment-
experienced (HR 1.74), cirrhosis (HR 2.63), and history of liver transplant (HR 1.5). History of
drug abuse (HR 0.43), elevated baseline ALT (HR 0.79), a history of hepatitis B virus infection
Real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection
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Table 1. Participant characteristics and demographics.
Characteristic DAA-Treated Cohort
(N = 830)
Untreated Cohort
(N = 7,577)
p value
Age, mean (SD) 56.9 (9.3) 52.1 (13.3) <0.0001
Sex, n (%)
Female 328 (39.5) 3,434 (45.3) 0.0014
Race, n (%)
Black 152 (18.6) 1,408 (18.9) 0.7948
White 654 (79.9) 5,917 (79.2)
Other 13 (1.6) 142 (1.9)
Missing, n 11 110
Ethnicity, n (%)
Hispanic or Latino 18 (2.2) 132 (1.8) 0.3915
Missing 13 164
Insurance, n (%)
Government 50 (6) 684 (9.1) <0.0001
Medicaid 131 (15.8) 1,639 (21.9)
Medicare 323 (39) 2,318 (31)
Private 301 (36.3) 2,000 (26.7)
Self-Pay 24 (2.9) 823 (11)
Workman’s Comp 0 14 (0.2)
Missing 1 99
ALT level, mean (SD), IU/L 54.1 (51.9) 45 (92.7) 0.0003
Missing, n 137 4128
Anxiety, n (%)
Yes 55 (6.6) 766 (10.1) 0.0013
APRI, mean (SD) 1.4 (1.5) 1.1 (2.1) <0.0001
Missing, n 158 4454
AST level, mean (SD), IU/L 55.9 (40.7) 47.3 (92.5) 0.0001
Missing, n 140 4154
Charlson Comorbidity Index, n (%)
0 294 (35.4) 5,943 (78.4) <0.0001
1 272 (32.8) 616 (8.1)
2 59 (7.1) 265 (3.5)
�3 205 (24.7) 753 (9.9)
Cirrhosis, n (%)
Yes 361 (43.5) 1,165 (15.4) <0.0001
CKD, n (%)
Yes 53 (6.4) 493 (6.5) 0.8932
Decompensated cirrhosis, n (%)
Yes 200 (24.1) 820 (10.8) <0.0001
Depression, n (%)
Yes 63 (7.6) 889 (11.7) 0.0003
Diabetes, n (%)
Yes 105 (12.7) 977 (12.9) 0.8422
Drug abuse, n (%)
Yes 48 (5.8) 965 (12.7) <0.0001
FIB-4, n (%)
>3.5 313 (46.6) 909 (29.3) <0.0001
(Continued)
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(HR 0.41), and self-pay for medical care (HR 0.39) were negatively associated with treatment
initiation (Table 3).
Manual chart review of a random sample from the untreated cohort (n = 287) suggests that
the most common reasons for lack of initiation of therapy were absence of patient follow-up
(33.7%) and insurance declined or other cost barrier (28.1%). Physician decision not to treat
accounted for 16% of non-initiation cases. The reasons for not initiating DAA therapy are
listed in S1 Table.
Table 1. (Continued)
Characteristic DAA-Treated Cohort
(N = 830)
Untreated Cohort
(N = 7,577)
p value
Missing, n 158 4474
Fibrosis stage, n (%)
F0 51 (6.6) 33 (14.7) <0.0001
F1 118 (15.3) 63 (28.1)
F2 87 (11.3) 36 (16.1)
F3 82 (10.6) 15 (6.7)
F4 433 (56.2) 77 (34.4)
Missing 59 7353
Genotype, n (%)
GT1 51 (6.4) 35 (1.4) <0.0001
GT1a 445 (56.1) 1,539 (60.8)
GT1b 117 (14.8) 407 (16.1)
GT2 93 (11.7) 257 (10.2)
Other 87 (11) 294 (11.6)
Missing 37 5045
HBV infection, n (%)
Yes 9 (1.1) 157 (2.1) 0.0522
HIV, n (%)
Yes 13 (1.6) 136 (1.8) 0.6355
History of kidney transplant, n (%)
Yes 14 (1.7) 53 (0.7) 0.0024
History of liver transplant, n (%)
Yes 117 (14.1) 336 (4.4) <0.0001
Neutropenia, n (%)
Yes 3 (0.4) 36 (0.5) 0.6473
Platelet count�100,000/μL, n (%) 468 (67.3) 2,933 (79.4) <0.0001
Missing, n 135 3,882
Previous treatment (interferon, pegylated interferon, ribavirin, first-generation DAAs), n (%)
Yes 212 (25.5) 536 (7.1) <0.0001
Thrombocytopenia, n (%)
Yes 19 (2.3) 99 (1.3) 0.0223
ß-blocker use, n (%)
Yes 318 (38.3) 3,377 (44.6) 0.0006
Proton pump inhibitor use, n (%)
Yes 306 (36.9) 3,211 (42.4) 0.0022
ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; CKD, chronic kidney disease; DAA, direct-
acting antiviral; FIB-4, Fibrosis 4; HBV, hepatitis B virus; HIV, human immunodeficiency virus.
https://doi.org/10.1371/journal.pone.0218759.t001
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Clinical characteristics and demographics of the treated cohort stratified by DAA regimen
are reported in S2 Table. Ribavirin was added to sofosbuvir/ledipasvir most commonly for
individuals with more advanced fibrosis, including compensated and decompensated cirrho-
sis, those with prior liver transplant, and those previously treated with an interferon-based
therapy.
Overall SVR rates and SVR by subgroup
In the evaluable population cohort (n = 423), 83.9% (95% confidence interval [CI] 81–87%) of
participants achieved SVR (Table 4). Excluding those who did not complete treatment, SVR in
the per-protocol population was 84.7% (343/405; 95% CI 81–88%) regardless of genotype. For
the evaluable population, SVR rates were 85.0% (153/180) in women, 83.1% (202/243) in men,
82.5% (104/126) in treatment-experienced participants, 78.2% (154/197) in cirrhotic partici-
pants, and 88.7% (220/248) in those with platelet count�100,000/μL. SVR rates were 84.7%
(261/308) in participants treated for 12 weeks versus 82.9% (68/82) in those treated for 24
weeks, and 83.3% (15/18) in those treated for 8 weeks in the evaluable population (Table 4).
Fig 1. Kaplan–Meier curve: Time to treatment initiation.
https://doi.org/10.1371/journal.pone.0218759.g001
Table 2. Distribution of direct-acting antiviral treatments and early treatment discontinuation by regimen.
Treatment Regimens
Treatment initiation/early
discontinuation
Sofosbuvir/
ledipasvir
Sofosbuvir/
ledipasvir
+ Ribavirin
Sofosbuvir
+ Ribavirin
Sofosbuvir/
simeprevir ± Ribavirin
PrOD ± Ribavirin Other DAA
Agents
Total
DAA therapy initiation, n (% of
total treatment initiations)
261 (31.45) 121 (14.58) 213 (25.66) 187 (22.53) 20 (2.41) 28 (3.37) 830a
(100.0)
Early discontinuation, n (% of total
early treatment discontinuations)
6 (2.30) 3 (2.48) 14 (6.57) 8 (4.28) 2 (10.00) 2 (7.14) 35
(4.22)
DAA, direct-acting antiviral; PrOD, paritaprevir/ritonavir/ombitasvir/dasabuvir.
a9.87% of 8,407 in total eligible cohort.
https://doi.org/10.1371/journal.pone.0218759.t002
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The SVR rates by DAA treatment are listed in S3 Table. Among participants with GT1
infection, the overall unadjusted SVR rate was 83.9%. SVR was achieved by 92.2% (n = 53/166)
of participants receiving sofosbuvir/ledipasvir, with slightly lower SVR rates in those with cir-
rhosis compared with no cirrhosis (88.9% vs. 94.2%). Of the 65 individuals who received sofos-
buvir/ledipasvir + ribavirin, 84.6% achieved SVR, with a slightly lower rate of SVR in cirrhotic
participants. The SVR rate among the 132 participants who received sofosbuvir/simeprevir ±
ribavirin was 79.6%, with lower rates in those with cirrhosis (73.4%) and treatment-experi-
enced individuals (79.3%). Ten individuals initiated treatment with PrOD ± ribavirin, with
an SVR rate of 90% (9/10). Forty-six individuals initiated therapy with sofosbuvir + ribavirin,
with an overall SVR rate of 65.2%, and 59.3% in those with cirrhosis.
The treatment discontinuation rate was 4.2%, ranging from 2.3% in people receiving sofos-
buvir/ledipasvir to 6.6% in those receiving sofosbuvir/ribavirin and 10% in those receiving
PrOD ± ribavirin.
Discussion
All-oral DAA therapy has revolutionized the treatment of chronic HCV infection. Before the
availability of DAA agents, SVR rates of up to 75% were observed in HCV GT1-infected indi-
viduals; however, side effects with interferon-based treatments were often severe, and many
individuals were not eligible for interferon therapy. SVR rates of>95% have been reported
with all-oral DAA combinations in individuals with GT1 infection, as confirmed in multiple
observational cohort studies [19–21]. However, the benefits of highly efficacious therapies may
be limited if these treatments cannot be accessed by those who require them. To date, data
Table 3. Predictors of initiation of direct-acting antiviral treatment by Cox regression analysis.
Characteristic Coefficient Hazard Ratio HR
Lower CL
HR
Upper CL
P value
Age 0.01 1.01 1.00 1.02 0.042
Female −0.32 0.73 0.51 1.03 0.074
Insurance
Medicaid −0.44 0.65 0.47 0.90 0.009
Medicare −0.32 0.72 0.53 0.98 0.039
Private −0.07 0.94 0.69 1.27 0.663
Self-Pay −0.93 0.39 0.24 0.64 <0.001
Workman’s Comp −10.06 0 0 1.35+143 0.954
Unknown insurance type −2.42 0.09 0.01 0.65 0.017
Elevated ALT levela −0.24 0.79 0.54 1.15 0.213
Cirrhosis 0.97 2.64 2.24 3.10 <0.0001
History of drug abuse −0.85 0.43 0.32 0.58 <0.0001
HBV infection −0.88 0.41 0.21 0.80 0.009
History of liver transplant 0.40 1.50 1.22 1.83 <0.001
Elevated platelet countb 0.15 1.16 0.97 1.39 0.112
Missing platelet data −0.38 0.69 0.50 0.94 0.018
Treatment-experienced 0.55 1.74 1.47 2.05 <0.0001
ALT, alanine aminotransferase; CL, confidence limit; HBV, hepatitis B virus; HR, hazard ratio.
aElevated ALT level: ALT�33 IU/L for males;�25 IU/L for females.
bElevated platelet count:�100,000/μL; low: <100,000/μL.
Positive references were male, treatment naive, and had government insurance, low ALT levels, no cirrhosis, no history of drug abuse, no HBV infection, no history of
liver transplant, low platelet count.
https://doi.org/10.1371/journal.pone.0218759.t003
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regarding the frequency of treatment initiation in the era of DAA therapy are limited. This
study therefore serves as a reference for newer DAA therapies with improved access to care.
The demographics of this study population mirror those of other HCV infection cohorts
reported in registration trials, with most participants being white males [2, 8, 9, 11]. The over-
all uptake of therapy among participants eligible for treatment during the first 2 years of the
DAA era was low at 9.9%, and was similar to that previously reported with interferon-based
treatments [22]. We observed an increase in the incidence of treatment initiation during the
second year of the study; however, a median time to initiation of therapy of 300 days suggests
that substantial improvements in overcoming barriers to treatment are still required. Insur-
ance type was a significant predictor of treatment initiation, with the highest rates seen in
those with Medicare and private insurance. Disease severity was also a predictor of initiation
of therapy, with higher rates in those with clinical features suggesting advanced liver disease,
including compensated and decompensated cirrhosis, greater Charlson comorbidity scores,
and a history of liver transplant. It is likely that the higher rates of treatment initiation in these
groups can be explained partially by their requirement for continuous medical care. Prior
treatment was also correlated with initiation of treatment, whereas a history of drug abuse was
Table 4. Sustained virologic response rates (95% confidence intervals) in participants with HCV GT1 infection who initiated direct-acting antiviral treatmenta.
Evaluable Population Per-Protocol Population
No. of Participants Achieving SVR,
% (95% CI)
n No. of Participants Achieving SVR,
% (95% CI)
n
All participants 355
83.92 (81–87)
423 343
84.69 (81–88)
405
8-week treatment 15
83.33 (59–96)
18 14
82.35 (57–96)
17
12-week treatment 261
84.74 (80–89)
308 260
85.25 (81–89)
305
24-week treatment 68
82.93 (73–90)
82 68
82.93 (73–90)
82
SVR by subgroup
Female 153
85.00 (79–90)
180 148
84.06 (79–90)
174
Male 202
83.13 (78–88)
243 195
84.42 (79–89)
231
Cirrhosis 154
78.17 (72–84)
197 149
78.42 (72–84)
190
No cirrhosis 201
88.94 (84–93)
226 194
90.23 (85–94)
215
Black 82
92.13 (84–97)
89 79
94.05 (87–98)
84
Non-black 273
81.74 (77–86)
334 264
82.24 (78–86)
321
Treatment-experienced 104
82.54 (75–89)
126 100
82.64 (75–89)
121
Treatment-naive 251
84.51 (80–88)
297 243
85.56 (81–89)
284
Platelet count�100,000/μL 220
88.71 (84–92)
248 211
89.79 (85–93)
235
Platelet count <100,000/μL 86
74.78 (66–82)
115 83
74.45 (66–83)
110
CI, confidence interval; DAA, direct-acting antiviral; GT, genotype; HCV, hepatitis C virus; SVR, sustained virologic response.
aSVR was estimated among participants with available SVR measurements.
https://doi.org/10.1371/journal.pone.0218759.t004
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negatively correlated with treatment initiation. The characteristics of our treatment cohort
mirror the population initially prioritized for treatment in guidelines and by private and public
insurers. Future studies should examine fibrosis status among those initiating therapy to deter-
mine if those with less severe disease and fewer comorbidities are also starting treatment. Cur-
rent guidelines emphasize that all individuals with HCV infection should receive DAA therapy
if they comply with the intended treatment [23]. More recent data suggest that individuals
with depression, illicit substance use, and other psychiatric disorders can be successfully
treated, with SVR rates similar to those without these comorbidities. It is also expected that
future studies will demonstrate that a history of drug abuse does not negatively correlate with
initiation of therapy [24, 25]. In our study, the highest rates of treatment initiation were 39%
and 36.3% in people with Medicare and private insurance, respectively, compared with only
15.9% of those with Medicaid. However, in several states treatment restrictions are gradually
being reduced, which, given the sizeable population of HCV-infected individuals with Medic-
aid as their primary insurance, should improve DAA therapy initiation rates.
The most common intended treatment duration was 12 weeks with sofosbuvir/ledipasvir,
with an overall SVR of 92.2% (n = 153/166). In people receiving sofosbuvir/ledipasvir, SVR
rates were lower in cirrhotic than in non-cirrhotic individuals (88.9% vs. 94.2%). Those who
received sofosbuvir/ledipasvir + ribavirin had an overall response rate of 84.6%, with no differ-
ence between treatment-naive and treatment-experienced individuals (84.2% vs. 85.2%).
Other reports confirm that the real-world effectiveness of DAA agents varies by HCV popula-
tion. HCV-TARGET is a prospective, longitudinal, observational study of patients with
chronic HCV infection at academic and community centers from the United States, Canada,
Germany, and Israel. This study has reported SVR rates of 84% in people with HCV GT1
infection receiving sofosbuvir/simeprevir for up to 16 weeks [19]; 94% in people with HCV
GT1 infection receiving sofosbuvir/ledipasvir for 12 or 24 weeks [26]; and 93% in individuals
with HCV GT1 infection receiving sofosbuvir/ledipasvir for 8 to 16 weeks [20]. In addition,
studies from the Veterans Affairs population in the United States and a large US commercially
insured population evaluating patients with HCV GT1 infection confirm SVR rates of 90% to
94% in individuals receiving sofosbuvir/ledipasvir [27–30].
An SVR rate of 79.5% was noted in those who received sofosbuvir/simeprevir with or with-
out ribavirin. The combination of sofosbuvir/simeprevir is approved for the treatment of
GT1-infected individuals [31]; however, in 2014 this was an off-label combination that repre-
sented the most efficacious regimen available for people with GT1 infection. In other real-
world settings, rates of SVR12 in people receiving sofosbuvir/simeprevir were 64% in those
with GT1a infection and 84% in those with GT1b infection [32]. SVR rates of 72% in those
with GT2 infection receiving sofosbuvir/ribavirin and 35% in those with GT3 infection receiv-
ing sofosbuvir/ribavirin are also reported [32].
Early discontinuation rates were low (4.2%), ranging from 2.3% in participants receiving
sofosbuvir/ledipasvir without ribavirin to 10% in those receiving PrOD ± ribavirin. These dis-
continuation rates are substantially lower than those reported with interferon-based therapy,
likely owing to the dramatically different tolerability profiles between DAA and interferon-
based treatments [3]. It is also apparent that discontinuation rates in the present study were
higher among participants receiving a ribavirin-containing regimen, possibly because of the
well-described tolerability profile of ribavirin. Welzel et al. also reported discontinuation rates
of 6.7% in people receiving sofosbuvir/ribavirin in a real-world setting; however, other studies
indicate that discontinuation rates with DAA therapies are similar (approximately 1% to 3%)
regardless of ribavirin use [19, 20].
This study had several limitations. The source of the database was a large center in Indiana;
thus, the findings may not be generalizable to the general US population. The study period
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included the first 2 years that all-oral DAA therapies were available; since this time, both
guidelines and insurers have broadened the criteria for treatment eligibility, with the present
American Association for the Study of Liver Diseases guidelines stating that all people with
HCV infection without a limited lifespan and who can comply with treatment should be con-
sidered for therapy. Since these data were collected, there have been substantial changes in the
use of DAA therapies for the treatment of HCV infection; these data are therefore unlikely to
accurately represent the current utilization of DAA treatments. The use of EMRs may limit the
granularity or the completeness of our data. We therefore implemented a manual chart review
to minimize the impact of missing values and to validate laboratory results.
Conclusion
Data from the present study provide insight into initiation of DAA therapy during the early
years of the availability of all-oral regimens. We found that treatment was initiated in 9.9%
of HCV-infected individuals and time to initiation was 300 days. Expanding treatment eligibil-
ity criteria and reducing economic barriers should increase rates of treatment initiation and
reduce time to treatment. Future studies, based on more recent treatment periods, are likely to
demonstrate improved access to treatment and broadened treatment eligibility including indi-
viduals with less advanced disease.
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